Bimekizumab well tolerated, efficacious over three years in axial spondyloarthritis

Medical Xpress

For patients with axial spondyloarthritis (axSpA), bimekizumab, a dual interleukin (IL)-17A and IL-17F inhibitor, is well tolerated over three years, according to a study published in the June issue of the Journal of Rheumatology. ...

전문 보기

이 뉴스, 어떠셨어요?

한 번의 탭으로 반응을 남겨요 · 로그인 불필요

Bimekizumab well tolerated, efficacious over three years in axial spondyloarthritis

이 뉴스, 어떠셨어요?

관련 뉴스

'science' 카테고리 뉴스

Parents direct more threats toward school administrators than teachers

Kids received mental health treatment in record numbers after pandemic, records show

Disordered collagen may help explain hip fractures beyond bone density, X-rays reveal

Medical Xpress의 다른 기사

New genetic switch could improve gene therapy for drug-resistant epilepsy

Current substance misuse prevention misses scale, argues paper; schools and digital tools could help

A call for greater focus on social factors that shape health